Lp(a): the genetic risk factor most doctors never test

You could have a normal LDL, a normal total cholesterol, a clean stress test, and still carry a cardiovascular risk factor that substantially increases your chance of a heart attack. It’s called Lp(a) — lipoprotein(a) — and roughly one in five people carries levels high enough to meaningfully raise cardiovascular risk.

Your doctor has almost certainly never tested it. Most don’t. A standard lipid panel shows LDL-C, HDL-C, and triglycerides. Lp(a) is not on it. One in five people walks around with a genetic risk factor that never appears on any lab report, never triggers a conversation, and never informs treatment decisions.

Here’s what it is and what it means if you have it.

What Lp(a) is — and what it isn’t

Lp(a) is a lipoprotein particle similar to LDL in structure, but with an extra protein called apolipoprotein(a) attached to it. That protein makes Lp(a) particles stickier and more prone to embedding in artery walls. It also gives Lp(a) prothrombotic properties: it interferes with the body’s clot-dissolving mechanisms, so it both builds plaque and makes the clots that form on plaque more dangerous.

Think of LDL and Lp(a) as two different vehicles delivering cholesterol into your artery walls. A standard lipid panel counts the cargo. It doesn’t distinguish which vehicles are doing the delivering. You can have “normal” LDL cholesterol and still have significant cardiovascular risk — the Lp(a) vehicles are doing damage that never shows up on the standard panel.

What Lp(a) is not:

• Not modifiable by lifestyle. Diet, exercise, and weight loss don’t meaningfully change Lp(a) levels. This is genetically determined.
• Not responsive to statins. Statins lower LDL and ApoB. They don’t lower Lp(a). Evidence from large trials suggests statins may modestly raise Lp(a) by roughly 10-15% — one reason that lowering ApoB via statin in someone with high Lp(a) doesn’t fully neutralize their atherogenic burden.
• Not something that needs retesting. Lp(a) is approximately 90% heritable and remains stable throughout adult life under normal conditions. You test it once. The number you get at age 35 will be essentially the same at age 65, barring major hormonal or metabolic changes such as thyroid dysfunction or nephrotic syndrome, which can shift levels modestly.

Why your doctor probably hasn’t tested it

The Lp(a) test costs $30-50 at most labs. No special preparation. Single blood draw, often from the same tube as your lipid panel. So why doesn’t it appear on standard screening?

The first reason is therapeutic. There’s no FDA-approved drug that specifically lowers Lp(a) as of 2026. Some clinicians reason: if you can’t directly treat it, why test it? That logic collapses fast. Knowing your Lp(a) changes how aggressively you manage everything else — your ApoB target, whether you start medication sooner, your entire cardiovascular risk picture.

The second reason is structural. Most primary care screening algorithms are built around population-level thresholds for common conditions. Lp(a) is a genetically variable risk factor that affects about 1 in 5 people. Population-level screening tools are built for majority patterns. Individual risk assessment requires the tests that standard screening skips.

What Lp(a) numbers mean

Lp(a) is measured in nmol/L (nanomoles per liter) or mg/dL. nmol/L is preferred because it directly counts particle number; mg/dL measures mass and is less accurate. The two units don’t convert by a fixed factor — don’t try to multiply between them.

How Protocol stratifies Lp(a) in our Cardiovascular Risk protocol:

Lp(a) Level	Risk Category	What It Means
Below 50 nmol/L	Normal	Does not meaningfully add to cardiovascular risk. No specific action needed. No retesting needed.
50-74 nmol/L	Modestly elevated	Contributes to risk tier assignment. No specific Lp(a) therapy available. Managed through more aggressive ApoB targets.
75-125 nmol/L	High	Classified as Tier B (High Risk) in Protocol’s system. ApoB target drops to below 60 mg/dL. All other modifiable risk factors managed aggressively.
Above 125 nmol/L	Very High	Classified as Tier A (Very High Risk). ApoB target drops to below 55 mg/dL. Immediate pharmacotherapy for ApoB. Zero tolerance for suboptimal management of any modifiable risk factor.

Lp(a) risk is additive — it stacks on top of whatever risk your ApoB, blood pressure, blood sugar, and other factors already create. An Lp(a) of 150 nmol/L in someone with an ApoB of 60 looks very different from the same Lp(a) in someone with an ApoB of 130. Both need attention, but the second person is accumulating risk from multiple directions at once.

Lp(a) risk is also independent. It doesn’t go away when you fix other numbers. Lowering your ApoB from 130 to 70 is excellent and necessary, but it doesn’t erase the Lp(a)-driven risk. It reduces your total risk by addressing what’s modifiable.

The “normal LDL” trap

This is where Lp(a) does the most damage — not because the molecule itself is more destructive, but because the false reassurance of a “normal” lipid panel leads to years of inaction.

A scenario that plays out constantly: A 45-year-old gets an annual physical. LDL-C comes back at 110 mg/dL. Doctor says, “Your cholesterol looks good.” Patient assumes they’re fine. Fifteen years later, they have a heart attack.

What the standard lipid panel missed: Lp(a) was 180 nmol/L. That Lp(a), combined with a not-actually-optimal LDL and 15 years of cumulative exposure, built enough plaque to cause an event. If Lp(a) had been tested at 45, the ApoB target would have been set below 55 mg/dL, pharmacotherapy would have started immediately, and 15 years of aggressive risk management would have cut that outcome probability substantially.

Studies estimate that elevated Lp(a) contributes to a meaningful share of cardiovascular events globally — events that disproportionately occur in people whose conventional risk markers looked reassuring.

If you’ve been told your cholesterol is “fine” but you’ve never had an Lp(a) test, you have incomplete information. Related reading: What to Do When Your ApoB Is High and What Borderline Cholesterol Actually Means.

What you can actually do about high Lp(a)

There is no approved therapy that specifically lowers Lp(a) as of 2026. Several agents target Lp(a) directly — pelacarsen, olpasiran, and lepodisiran have shown reductions of 80% or more in Phase 2 data — but none have received FDA approval for this indication. Outcome trial data are still maturing. When an agent clears that bar, the management picture will change substantially.

Until then: lower everything else more aggressively.

Lower ApoB more aggressively

If you can’t reduce the Lp(a) particles directly, you reduce every other atherogenic particle as much as possible. That means a lower ApoB target — below 60 mg/dL for Lp(a) 75-125, below 55 mg/dL for Lp(a) above 125. These targets are more aggressive than what most guidelines recommend for the general population, deliberately so.

Someone with high Lp(a) is more likely to need pharmacotherapy (a statin, ezetimibe, or both) and more likely to need it sooner. Lifestyle interventions — Mediterranean diet, regular exercise, omega-3 supplementation — are still part of the plan, but alongside medication, not instead of it.

For the full picture on how ApoB and Lp(a) interact in Protocol’s risk model, read The ApoB-Lp(a) Connection: Why Both Numbers Matter.

Optimize every modifiable risk factor

When one major risk factor is genetically fixed, every controllable factor carries more weight. Blood pressure at 135/85 instead of 120/75 matters more when Lp(a) is elevated. A fasting insulin of 14 instead of 6 matters more. Smoking, even occasional, matters more. Each additional risk factor compounds with the Lp(a)-driven risk.

Protocol’s approach with high Lp(a) members is explicit: zero tolerance for anything suboptimal that can be fixed. ApoB at target, blood pressure managed to a tight range, insulin sensitivity verified, exercise prescription met, diet on protocol. No single change erases the genetic risk — but doing all of it creates the best outcome possible given the biology you were dealt.

PCSK9 inhibitors — a partial answer

PCSK9 inhibitors (evolocumab and alirocumab) are primarily prescribed for aggressive ApoB/LDL lowering, but they also reduce Lp(a) by approximately 20-30%. They’re not prescribed specifically for Lp(a), but this secondary effect gives them additional weight in the pharmacotherapy decision for members with high Lp(a) who need aggressive ApoB management. Protocol’s escalation algorithm accounts for this at steps 3 and 4.

Screen your family

Lp(a) is genetic. If yours is elevated, your first-degree relatives — parents, siblings, children — have a real chance of carrying the same risk factor. A single blood test can determine whether they do. Protocol recommends cascade screening for all first-degree relatives of members with Lp(a) above 75 nmol/L.

One test, drawn from the same tube as a standard lipid panel, can change how a person’s cardiovascular risk is managed for the rest of their life.

What happens when Lp(a)-lowering drugs arrive

Pelacarsen, olpasiran, and lepodisiran use distinct mechanisms to reduce Lp(a) production, and Phase 2 data demonstrated reductions of 80% or more. Outcome trials are testing whether those particle reductions translate to fewer heart attacks and strokes — the endpoint that actually matters.

If these trials succeed, it changes the management of elevated Lp(a) in a fundamental way — for the first time, you’d be treating the genetic risk factor itself, not working around it. Protocol is tracking these trials. When something gets approved, we’ll be having that conversation with affected members.

For now, there’s one thing to do: get tested. If your number is below 50 nmol/L, you know Lp(a) isn’t a factor and you can move on. If it’s elevated, you now have information that changes how aggressively everything else gets managed. That’s not nothing.

How Protocol tests Lp(a)

In Protocol’s Cardiovascular Risk protocol, Lp(a) is part of the baseline testing panel for every member. One test. One time. It costs $30-50 and it’s included in the initial lab draw alongside ApoB, a full lipid panel, and hsCRP.

When results come back, Lp(a) gets a dedicated discussion — not buried in a lab printout, not glossed over in a list of 20 values. If your Lp(a) is elevated, you leave that encounter knowing exactly what it means, how it changes your risk tier, what your specific ApoB target is, and what the management plan looks like.

You also leave knowing this number is genetic. Not your fault. Not caused by anything you did or didn’t eat. It’s information — information that changes how we manage your cardiovascular health going forward.

Many of our members discover elevated Lp(a) for the first time during their initial assessment, including people who’ve had “normal” annual physicals for decades. The test was always available. It just wasn’t ordered.

The one-test argument

Ask your doctor to order an Lp(a) test. Or order it yourself through a direct-to-consumer lab — it runs $30-50. You only need to do it once.

Below 50 nmol/L: Lp(a) is not a factor. You never need to think about it again.

Elevated: a risk factor that was quietly shaping your cardiovascular future is now visible and quantifiable. You can’t change Lp(a) itself — not yet — but you can manage everything around it more precisely than you could before you knew.

Roughly one in five people carries this. Most will never know. A single $30 test determines which group you’re in.

---

Ready to find out where you stand? Protocol’s Foundation Assessment measures what your annual physical misses — ApoB, HOMA-IR, DEXA body composition, VO2 max — and builds a specific action plan from the data.

Book a Discovery Call —>